Copyright
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1552-1567
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1552
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1552
Table 2 Twenty-four hours urine copper and non-ceruloplasmin copper in various stages of Wilson’s disease treatment
Early stages of treatment (< 1 yr) | UCu > 500 μg/dNCC > 25 μg/dL |
Good control (treatment > 1 yr) | UCu 200-500 μg/dNCC < 15 μg/dL |
Poor compliance/uncontrolled disease | UCu > 500 μg/dNCC > 15 μg/dL |
Inadequate dose | UCu < 200 μg/dNCC > 15 μg/dL |
Over-treatment | UCu < 200 μg/dNCC < 5 μg/dL |
- Citation: Seetharaman J, Sarma MS. Chelation therapy in liver diseases of childhood: Current status and response. World J Hepatol 2021; 13(11): 1552-1567
- URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1552.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1552